Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 7/20 | 0.49 |
| ▸ | BRD4 | O60885 | 11/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 11/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23301264 | 1.00 | PRKCZ (0.49) | PRKCZBRD4ATAD2ABL1MEN1 | |
| SCHEMBL30175633 | 0.94 | PRKCZ (0.57) | PRKCZBRD4ATAD2ABL1PRKD2 | |
| SCHEMBL30175652 | 0.94 | PRKCZ (0.57) | PRKCZBRD4ATAD2ABL1PRKD2 | |
| SCHEMBL23328179 | 0.94 | PRKCZ (0.57) | PRKCZBRD4ATAD2ABL1PRKD2 | |
| SCHEMBL23328145 | 0.94 | PRKCZ (0.57) | PRKCZBRD4ATAD2ABL1PRKD2 | |
| SCHEMBL23328171 | 0.94 | PRKCZ (0.57) | PRKCZBRD4ATAD2ABL1PRKD2 | |
| SCHEMBL30175628 | 0.90 | PRKCZ (0.51) | PRKCZABL1KMT2APRKD2 | |
| SCHEMBL23328175 | 0.90 | PRKCZ (0.51) | PRKCZABL1KMT2APRKD2 | |
| SCHEMBL23301038 | 0.90 | PRKCZ (0.51) | PRKCZBRD4ATAD2ABL1PRKD2 | |
| SCHEMBL29897358 | 0.90 | PRKCZ (0.51) | PRKCZBRD4ATAD2ABL1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | claimed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | claimed |
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-4051664-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | Cancer Research Technology Limited (GB) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | PRKCZ 717/4885BRD4 517/4885ATAD2 1887/4885 |
| US-20230045929-A1 | ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS | SIK2, SIK3, SIK1 | PRKCZ 875/4885BRD4 321/4885ATAD2 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.